• Title/Summary/Keyword: Pharmaceutical Industry of Korea

Search Result 258, Processing Time 0.025 seconds

How to Enhance International Competitiveness of Korean Pharmaceutical Industry with CEPA as a momentum?

  • Park, Hyun-Chae
    • THE INTERNATIONAL COMMERCE & LAW REVIEW
    • /
    • v.48
    • /
    • pp.101-125
    • /
    • 2010
  • CEPA(Comprehensive Economic Partnership Agreement, hereinafter CEPA) between India and Korea may influence some changes on Korean pharmaceutical industry which shows less competitive advantages than Indian industry in many regards. So the purpose of this paper remains on suggesting the way of enhancing international competitiveness for Korean industry on the basis of double diamond model. Through the comprehensive and deep analysis, our findings on recommendable business strategies for Korea are as follows ; in terms of factor conditions, first, cooperative strategy in R&D for developing generics will be required. Second, Introduction of CMO business can be considered. In terms of demand condition, Korean firms should find out the chance for demand creation in Indian market which has future market potential and American market exploration, as soon as possible. With regards to strategy, structure and competition, trying M&A with leading Indian companies and utilizing well organized medical professionals in India will be considered. In the points of related and supportive parts, lastly, Korean government should try to make so called "National Strategic R&D committee" for pharmaceuticals and bring u-healthcare service to Korea in the first place. If Korean pharmaceutical industry implement above-mentioned strategies, CEPA can be turned into business opportunities from the crisis. As a result, Korean firms shall have more powerful global competitiveness eventually.

  • PDF

Control of Uniformity in the Drug Industry By focusing on solid dosage forms for internal use

  • Lee, Seung-Woo
    • Proceedings of the PSK Conference
    • /
    • 2003.10a
    • /
    • pp.40-41
    • /
    • 2003
  • The present topic in pharmaceutical industry is to establish Quality Assurance System for medicinal product Therefore, the most important and urgent subject to be solved in the field of the manufacturing industry is to establish, implement and maintain the control system for ensuring uniformity of medicinal product. In case of solid dosage forms for internal use, its quality was controlled by disintegration test, etc but at present bioavailability could be predicted with dissolution test and so the assurance of its uniformity should be prerequistie to preserve suitable dissolution of the manufactured medicinal product. (omitted)

  • PDF

A Strategy of Improved Formulation Development in Pharmaceutical Industry

  • Shin, Hee-Jong
    • Proceedings of the PSK Conference
    • /
    • 2003.10a
    • /
    • pp.44-46
    • /
    • 2003
  • Although Cyclosporin A (CsA) is a powerful immunosuppresant with little adverse effect on the bone marrow, CsA administered orally in the general formulation cannot obtain high bioavailability due to its poor aqueous solubility. To improve the solubility and enhance the bioavailability of poorly water-soluble CsA, many different approaches have been made in our laboratory. (omitted)

  • PDF

FDI Spillover Effects on the Productivity of the Indian Pharmaceutical Industry: Panel Data Evidence

  • DESAI, Guruprasad;SRINIVASAN, Palamalai;GOWDA, Anil B
    • The Journal of Asian Finance, Economics and Business
    • /
    • v.9 no.8
    • /
    • pp.109-121
    • /
    • 2022
  • The study empirically examines the horizontal spillover effects of foreign direct investment (FDI) on the productivity of Indian pharmaceutical firms. Robust least squares and the Generalized Method of Moments estimators are applied for the firm-level panel data of Indian pharmaceutical companies whose shares were traded on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). The information was collected from the Centre for Monitoring Indian Economy (CMIE) Prowess database from 2015 to 2019. Based on the regularity in data availability, the sample firms are limited to 112 companies, 100 of which are domestic firms and 12 international firms. Firms with more than 10 percent foreign equity are classified as FDI firms, while those with less than that are classified as domestic firms. Estimation results show that foreign ownership does not contribute to the productivity of domestic firms. Due to increased competition, the Indian pharmaceutical companies with foreign equity participation are not more productive than local ones. Moreover, the findings reveal a negative and insignificant horizontal spillover effect from FDI on the productivity of domestic enterprises. The absence of horizontal spillovers may be attributable to foreign enterprises' ability to prevent technological outflow to competitors in the same industry.

The economic effect of Korea-EFTA Mutual Recognition Agreement in the pharmaceutical industry using Conditional Valuation Method (CVM) (조건부가치평가법(CVM)을 이용한 한-EFTA간 제약 산업 상호인정협약 체결의 경제적 효과 분석)

  • Kwon, Tae-Hyuk;Lee, Sang-Won
    • Journal of the Korea Academia-Industrial cooperation Society
    • /
    • v.19 no.5
    • /
    • pp.389-398
    • /
    • 2018
  • An MRA is considered to be an important policy tool within the WTO for overcoming technical barriers to trade. A number of studies on the economic impact of MRAs have demonstrated their positive economic effects. However, no studies have been conducted on MRAs in the pharmaceutical industry since analysis has been limited to industries as a whole or certain industries where some data were accumulated. Therefore, this paper analyzed the economic impact of MRAs for GMP inspection exemption in the pharmaceutical industry through the Conditional Valuation Method (CVM), a valuation technique for non-market goods. Pharmaceutical companies were asked whether or not they were willing to pay for the Korea-EFTA MRA through double-bounded dichotomous choice (DBDC) questions. The final WTP was estimated using the utility difference model developed by Hanemann (1984). As a result, annual economic effects on the pharmaceutical industry were estimated to be between KRW7.03 billion to KRW15.8 billion.

Determinants of Sustainability Performance in Pharmaceutical Distribution Industry

  • KIM, Yong-Ha;KIM, Young-Taek
    • Journal of Distribution Science
    • /
    • v.18 no.12
    • /
    • pp.91-100
    • /
    • 2020
  • Purpose: The objective of this study is to deepen our understanding of the key factors that determine sustainability in terms of suppliers based on the transactions between suppliers (pharmaceutical companies) and buyers (medical institutions) in the pharmaceutical distribution industry. Research design, data and methodology: Transaction justice factors were derived from three main components: distributive, procedural and interpersonal, five hypotheses were set up. The respondents from the data collected through an online survey are sales staff of pharmaceutical companies. Total of 319 questionnaires are collected and used to verify the hypotheses through the SPSS 22.0 and AMOS 22.0 programs. Results: Justice of transactions perceived by the salesperson of pharmaceutical companies was found to have a significant effect on the relationship commitment. Among them, procedural justice was found to have greatest relative influences. In addition, relationship commitment was found to have a significant effect on sustainability performance. Thus, all hypotheses were adopted. Conclusions: The results of this study, can be used as basic data for the guidelines for fair trade between pharmaceutical companies and medical institutions. In addition, it is expected that the study will have significance in that it examined sustainability through transactions with buyers from the viewpoint of suppliers.

Effects of the Korean Pharmaceutical Export Supporting Program's Service Quality on Export Performance Expectation of Korean Pharmaceutical Companies (국내 제약 산업 수출지원서비스 품질이 기업의 수출 기대치에 미치는 영향)

  • Lee, Seong-Bin;Lee, Sang-Won
    • The Korean Journal of Health Service Management
    • /
    • v.13 no.3
    • /
    • pp.105-114
    • /
    • 2019
  • Objectives: This study aimed to provide a comprehensive analysis of the relationship between the service quality of the Korea Health Industry Development Institute (KHIDI), along with the utilization of and customer satisfaction with its export supporting program, and the export performance of Korean pharmaceutical companies. Methods: An online and offline survey was conducted on Korean pharmaceutical companies that have used the export supporting program provided by KHIDI. Data on the service quality of KHIDI, utilization of and customer satisfaction with the export supporting program, and company export performance were collected via survey. Results: Results indicated that systemizing and reliability service factors of the export supporting program have a significant impact on customer satisfaction, and customer satisfaction has a significant impact on utilization of the export supporting program. Furthermore, customer satisfaction and utilization of the program have a significant impact on company expectations regarding future export performance. Conclusions: As a result, service quality, utilization, and customer satisfaction were found to affect Korean pharmaceutical company's expectations regarding their future export performance. The results of this study can significantly impact the development of export supporting programs.

Climate Change Disclosure Performance of Pharmaceutical Industry of Bangladesh

  • DAS, Shaily;JENI, Fatema Akter
    • Asian Journal of Business Environment
    • /
    • v.11 no.4
    • /
    • pp.39-45
    • /
    • 2021
  • Purpose: This study is designed to investigate the extent and nature of climate change disclosure of listed pharmaceutical companies of Bangladesh. Research design, data and methodology: In order to perform this research, a content analysis methodology is used. A climate change disclosure index is constructed to examine 12 different climate change disclosure issues. Information is collected from the annual reports of 29 pharmaceutical companies listed on the Dhaka Stock Exchange for the year 2019. Results: This study finds that only 48.28% of the sample companies provided disclosure on at least one issue regarding climate change. 'Energy savings' is the mostly disclosed issue whereas 'Pollution control expenditure', 'Biodiversity conservation initiatives' are the least disclosed issues. Research implication: This study concludes 64.29% of the companies examined, use less than five sentences for climate change disclosure, which depicts unsatisfactory disclosure practices regarding climate change issues. Study findings would be helpful for different industries of Bangladesh to implement efficient climate change reporting Practice. Future studies can be conducted on other industries to obtain more comprehensive result.

Study on Medicine Related Policies for Management Strategies and Performances of the Pharmaceutical Industry (제약산업의 경영전략, 경영성과에 의약품관련정책이 미치는 영향에 관한 연구)

  • Jung, Jae-Hoon;Cho, Duk-Young;Choi, Suhe-yong
    • The Korean Journal of Health Service Management
    • /
    • v.9 no.4
    • /
    • pp.157-169
    • /
    • 2015
  • Objectives : The aim of this study was to investigate the effect of various Republic of Korea policies, including the medicine cost rationalization policy implemented By investigating the management strategy/performance changes of the industry caused by such policies. Methods : Pharmaceutical companies listed on the national stock exchange and the KOSDAQ were examined for 10 years from 2004 to 2013. Their financial statements were collected and market changes before and after drug price policy implementations were compared. Results : From the result of this research, among the medicine related policies, the drug price rationalization policy was found to have a significant effect on business management strategies in terms of safety, profitability and growth potential after its implementation. After the drug pricing transparency policy was implemented, management strategies were affected significantly in terms of safety and profitability. Conclusions : As a result, all of the medicine related policies were found to have regulatory effects. Based on these findings, implications, research limitations and future study plans are presented.